The Northwest Cancer Patient Summit

#NWCS

WHEN 03/16/2019 12:30 PM
WHERE Bellingham, WA 3333 Squalicum Pkwy

About the NWCS

The Northwest Cancer Patient Summits are free patient education programs designed to help cancer patients and their caregivers understand various aspects of managing their cancer. These reoccurring forums feature live-interactive lecturers and panel discussions. Various cancer related topics are discussed, including cancer treatments, cancer prevention, management of side-effects, disease- or treatment-specific education, and other topics that help cancer patients make informed healthcare decisions and that help improve the quality of life of cancer patients.

TOPICS - The 6th NWCS

New updates immunotherapy

  • Checkpoint inhibitors
  • Beyond checkpoint inhibitors
  • Targeted therapy - newer agents in cancer treatment

  • Breast cancer
  • Lung cancer
  • Red flags you need to know for cancer recurrence

    Tips to stay financially sound during and after cancer treatment

    SPONSORS

    The 6th Northwest Cancer Patient Summit was supported by grants from:

    Exelixis

    Genentech

    We would also like to thank the bronze sponsors of this event:

    Amgen & Bristol-Myers Squibb

    The 5th Northwest Cancer Patient Summit on October 16, 2018 was supported by grants from :

    Exelixis

    Genentech

    We would also like to thank our sponsors of the 5th Northwest Cancer Patient Summit:

    Silver

    Puma, Pfizer, Teva

    Bronze

    AstraZeneca, Seattle Genetics, Tesaro


    We invite non-profits, local businesses, industry representatives, and others interested in cancer care to support this cancer patient education program as a sponsor, exhibitor, or partner. Sponsorship helps us to keep this event free for the community.

    There are various levels of sponsorship & exhibit opportunities available. Please email [email protected] with your inquiries about sponsorship and exhibition.

    Co-Sponsors

    PeaceHealth

    Partners

    YMCA

    Leukemia & Lymphoma Society

    EndBrainCancer